104 Chapter 5 Figure S3. Association of Kaplan-Meier estimates of progression free survival with CPS score Figure S4. Pharmacokinetic analyses The percentage injected dose (%ID/g) as measured in plasma at the day of [89Zr]Zr-DFO-durvalumab infusion (day 0) and at the day of PET/ CT (day 5) is visualized per cohort; cohort 1 (blue dots), cohort 2 (yellow squares), cohort 3 (red triangles).
RkJQdWJsaXNoZXIy MTk4NDMw